Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Central Review Likely For Novel Surrogate Endpoints

This article was originally published in The Pink Sheet Daily

Executive Summary

CDER’s Woodcock says accelerated approval requirements in 21st Century Cures legislation could create a process akin to how FDA handles breakthrough designations.

You may also be interested in...



US FDA Hoping To Solve Drug-Software Issues With Digital Health Working Group

As more applications include software components, group wants assessors to apply best practices from CDRH to CDER whenever possible.

PDUFA Budgeting: What Will Get Added, Subtracted – Or Multiplied By Cures?

Industry official sees potential for some streamlining in user fee program, but adding to breakthrough and patient-centered activities seems most likely.

Cures Excitement May Wane While Senate Works

Senate Health Committee continues work on its own 21st Century Cures-related legislation, meaning the newly passed House bill will be out of the spotlight for a bit.

Related Content

Topics

UsernamePublicRestriction

Register

PS078595

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel